These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 11479694)
21. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117 [TBL] [Abstract][Full Text] [Related]
22. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE. Ebert W; Hoppe M; Muley T; Drings P Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552 [TBL] [Abstract][Full Text] [Related]
23. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer. Chantapet P; Riantawan P; Lebnak P; Getngern P J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698 [TBL] [Abstract][Full Text] [Related]
24. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. Muley T; Dienemann H; Ebert W Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606 [TBL] [Abstract][Full Text] [Related]
25. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma. Lin WY; Yen TC; Cheng KY; Wang SJ Neoplasma; 1998; 45(1):21-4. PubMed ID: 9604997 [TBL] [Abstract][Full Text] [Related]
26. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651 [TBL] [Abstract][Full Text] [Related]
28. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443 [TBL] [Abstract][Full Text] [Related]
29. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer]. Li R; Li R; Wang Y Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296 [TBL] [Abstract][Full Text] [Related]
30. CYFRA 21-1 in the early diagnosis of recurrent disease in non small cell lung carcinomas (NSCLC). Stieber P; Zimmermann A; Reinmiedl J; Müller C; Hoffmann H; Dienemann H Anticancer Res; 1999; 19(4A):2665-8. PubMed ID: 10470216 [TBL] [Abstract][Full Text] [Related]
31. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer. Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Kameyama M; Suehiro S Ann Thorac Surg; 2007 Jan; 83(1):216-21. PubMed ID: 17184666 [TBL] [Abstract][Full Text] [Related]
32. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318 [TBL] [Abstract][Full Text] [Related]
33. Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN). Niemann AM; Goeroegh T; Gottschlich S; Lippert BM; Werner JA Anticancer Res; 1997; 17(4B):2859-60. PubMed ID: 9329547 [TBL] [Abstract][Full Text] [Related]
34. [Clinical usefulness of serum assay of EIA-CYFRA 21-1 in lung cancer]. Satoh H; Yagyu H; Sumi M; Ishikawa H; Hamada M; Suyama T; Naitoh T; Inoue M; Saitoh T; Uchida Y Gan To Kagaku Ryoho; 1994 May; 21(6):795-9. PubMed ID: 7514388 [TBL] [Abstract][Full Text] [Related]
35. CYFRA 21-1 serum analysis in patients with esophageal cancer. Brockmann JG; St Nottberg H; Glodny B; Heinecke A; Senninger NJ Clin Cancer Res; 2000 Nov; 6(11):4249-52. PubMed ID: 11106239 [TBL] [Abstract][Full Text] [Related]
36. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Ebert W; Muley T; Drings P Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537 [TBL] [Abstract][Full Text] [Related]
37. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728 [TBL] [Abstract][Full Text] [Related]
38. [Interleukin 3 (IL-3) in diagnosis and monitoring of non-small-cell lung cancer]. Mroczko B; Szmitkowski M; Czygier M Przegl Lek; 1999; 56(12):763-6. PubMed ID: 10789186 [TBL] [Abstract][Full Text] [Related]
39. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098 [TBL] [Abstract][Full Text] [Related]
40. [CYFRA 21-1: initial experiences in bronchus carcinoma and other tumors]. Hoefliger M; Morant R; Riesen W; Baumgartner G; Engler H Schweiz Med Wochenschr; 1994 Nov; 124(44):1966-70. PubMed ID: 7973529 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]